However, patients with mutations in SRSF2 and U2AF1 have been shown to have an adverse outcome in MDS and AML (38, 75–77), while others showed no significant prognostic impact of mutations in U2AF1, ZRSR2, and SF3B1 on patients’ outcome (78). The gene discussed is U2AF1; the disease is myelodysplastic syndrome.